美中嘉和醫學技術發展集團股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：2453） 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不就因本公告全部或任何部分內容而產生或因倚 賴該等內容而引致之任何損失承擔任何責任。 CONCORD HEALTHCARE GROUP CO., LTD. 誠如該公告所披露，浦發銀行同意向廣州醫院授出高達人民幣13億元的非循環信 貸。根據授信額度協議的條款及條件，並為進一步擔保本公司於授信額度協議項 下的責任及提供額外擔保，於2025年8月26日，本公司控股股東（定義見上市規 則）北京泰和誠醫療技術有限公司（「北京泰和誠」）同意以浦發銀行為受益人質押 本公司35.6百萬股H股，相當於北京泰和誠直接持有本公司股份總數約99.99%。 於本公告日期，北京泰和誠質押的本公司H股合共約佔本公司已發行股份總數約 4.54%。 就董事所深知，浦發銀行為本公司及其關連人士的獨立第三方。 承董事會命 美中嘉和醫學技術發展集團股份有限公司 董事長兼執行董事 楊建宇 中華人民共和國北京，2025年8月2 ...

Core Viewpoint - The approval of the first Aβ-PET imaging agent in China marks a significant breakthrough in the early diagnosis of Alzheimer's disease (AD), potentially advancing diagnosis by 15-20 years [1][2]. Company Overview - Meizhong Jiahe Medical Technology Development Group is a leader in high-end medical imaging diagnostics in China, with its Shanghai Meizhong Jiahe Medical Imaging Diagnosis Center playing a crucial role in the high-end medical market in Shanghai [2][3]. - The center is equipped with advanced imaging technologies, including GE Signa PET/MR, PET/CT, and others, providing diagnostic services to multiple medical institutions in the region [3]. Industry Impact - The introduction of the Aβ-PET imaging agent is expected to enhance the professional image of Meizhong Jiahe in the medical imaging sector and facilitate collaborations with top medical institutions and research teams [2]. - The center's innovative business model, which combines independent third-party services with shared imaging resources and remote diagnostics, demonstrates significant growth potential in the medical imaging service market [3]. Technological Innovation - The center has developed an AI-assisted diagnostic evaluation system in collaboration with Hexin Health, which screens critical health indicators and generates comprehensive reports, significantly reducing the risk of missed diagnoses [4]. - The ongoing demand for precision medicine is likely to further solidify the center's leading position in the high-end imaging service market [4].

Core Insights - The approval of the first Aβ-PET imaging agent, Fluorine-18 labeled beta-phenyl injection, marks a significant breakthrough in early diagnosis of Alzheimer's disease (AD) in China, potentially advancing the diagnosis timeline by 15-20 years [1] - China has approximately 9.83 million AD patients, the highest globally, with projections indicating this number will exceed 19 million by 2030 [1] - Early and precise diagnosis of AD is crucial due to the disease's insidious onset and progressive nature, highlighting the importance of this new diagnostic tool [1] Company Overview - Shanghai Meizhong Jiahe Medical Imaging Diagnostic Center, a subsidiary of Meizhong Jiahe, plays a pivotal role in the high-end medical market in Shanghai, solidifying its leadership position with the implementation of the "gold standard" for early AD diagnosis [2] - The center integrates advanced medical resources and promotes innovative medical technology applications, showcasing the company's strong resource integration capabilities and industry insight [2] - The center is equipped with cutting-edge imaging diagnostic equipment, providing services to multiple medical institutions in the region, thus enhancing the overall healthcare service network [3] Business Model and Growth Potential - The center's innovative business model, characterized by independent third-party services and remote radiation sharing, has created a replicable profit model, significantly improving operational efficiency and demonstrating substantial growth potential in the medical imaging service market [4] - This asset-light, high-value operation model is expected to serve as a strategic hub for Meizhong Jiahe's nationwide medical resource integration, enhancing the company's valuation through economies of scale and technological barriers [4] - The AI-assisted diagnostic evaluation system developed in collaboration with Hexin Health enables comprehensive screening of critical health indicators, significantly reducing the risk of missed diagnoses and optimizing resource allocation [4] Future Outlook - With the ongoing demand for precision medicine, the Shanghai Meizhong Jiahe Medical Imaging Diagnostic Center is poised to further strengthen its leading position in the high-end imaging service market [5] - Meizhong Jiahe, as a rare "full-chain high-end medical service provider" in the Hong Kong stock market, has established a complete medical service ecosystem across various fields, enhancing its overall competitiveness in precision medicine [5] - The strategic layout aims to benefit patients while enabling the group to achieve economies of scale and continuous marginal benefit, ultimately creating long-term stable value returns for investors [5]

Core Viewpoint - Meizhong Jiahe (02453.HK) announced that it will hold a board meeting on August 28, 2025, to review and approve the interim results for the six months ending June 30, 2025, and to consider the proposal for an interim dividend distribution, if any [1] Group 1 - The board meeting is scheduled for August 28, 2025 [1] - The meeting will focus on the interim results for the six months ending June 30, 2025 [1] - The company will also consider the proposal for an interim dividend distribution [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不就因本公告全部或任何部分內容而產生或因倚 賴該等內容而引致之任何損失承擔任何責任。 董事會會議日期 美中嘉和醫學技術發展集團股份有限公司（「本公司」，連同其附屬公司，統稱「本 集團」）董事（「董事」）會（「董事會」）謹此宣佈，董事會會議將於2025年8月28日 （星期四）舉行，藉以（其中包括）考慮及批准本集團截至2025年6月30日止六個月 未經審核業績及其發佈，並考慮派發中期股息（如有）。 承董事會命 美中嘉和醫學技術發展集團股份有限公司 董事長兼執行董事 楊建宇 中華人民共和國北京，2025年8月18日 於本公告日期，董事會包括(i)執行董事楊建宇博士、付驍女士及常亮先生；(ii)非 執行董事王雷先生、宋清寶先生及施波濤先生，及(iii)獨立非執行董事李雪梅女 士、孫延生先生及吳國賢先生。 CONCORD HEALTHCARE GROUP CO., LTD. 美中嘉和醫學技術發展集團股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：2453） ...

Core Insights - The article highlights the changes in the Hong Kong Stock Connect holdings, indicating significant increases and decreases in ownership percentages for various companies [1][2]. Group 1: Increased Holdings - Longpan Technology (02465) saw the largest increase in holdings, up by 3.25% to a total of 46.51% [1] - Derin Holdings (01709) experienced a 2.51% increase, bringing its total to 25.62% [1] - HuTongDa Network (09878) increased by 2.39%, reaching 29.81% [1] - In the last five trading days, Changfei Optical Fiber Cable (06869) had the highest increase at 7.59%, with a total holding of 53.37% [1] - Derin Holdings (01709) also saw a significant increase of 7.29% [1] Group 2: Decreased Holdings - Kailaiying (06821) had the largest decrease in holdings, down by 3.38% to 47.22% [1] - Dongyang Sunshine Pharmaceutical (06887) decreased by 1.55%, now at 51.49% [1] - Fubo Group (03738) saw a reduction of 1.26%, with a current holding of 34.52% [1] - Over the last five trading days, Hengsheng China Enterprises (02828) experienced the most significant drop at -16.55%, now at 2.47% [1] Group 3: Long-term Trends - Over the past 20 days, Changfei Optical Fiber Cable (06869) had a substantial increase of 24.95%, reaching 53.37% [1] - Derin Holdings (01709) increased by 10.51% over the same period, now at 25.62% [1] - The data indicates a trend of fluctuating investor interest in various sectors, with some companies gaining traction while others are losing it [1][2].

Core Insights - The Guangzhou Taihe Tumor Hospital Proton Therapy Center, under Meizhong Jiahe (02453.HK), ranked third in the "2024-2025 China Proton and Heavy Ion Center Rankings," highlighting its excellence in the field of proton therapy [1] Group 1: Rankings and Recognition - The ranking is based on a comprehensive indicator system centered around patient needs and operational excellence, developed with input from 21 experts with over 20 years of experience in radiation therapy [1] - The top two centers in the ranking are Shandong Provincial Tumor Hospital Proton Center and Shanghai Proton and Heavy Ion Hospital [1] Group 2: Equipment and Technology - Guangzhou Taihe Tumor Hospital is equipped with the latest Varian ProBeam proton therapy system, which offers advanced intensity-modulated proton therapy (IMPT) [2] - The superconducting cyclotron can accelerate proton beams to 60.84% of the speed of light, with a wide energy adjustment range for treating tumors at various depths [2] - The pencil beam scanning treatment head allows for precise irradiation with a minimum proton beam diameter of 3mm, minimizing damage to healthy tissue [2] Group 3: Medical Team and Clinical Capabilities - The medical team consists of leading experts in proton therapy, including key authors of the first "Proton and Heavy Ion Therapy Guidelines" in China, with extensive clinical and research experience [2] - The hospital has successfully treated a diverse patient population, with conditions ranging from nasopharyngeal cancer to pancreatic cancer, achieving significant treatment outcomes [3] Group 4: Compliance and Quality Control - The hospital adheres to strict compliance and quality control measures, guided by MD Anderson Cancer Center protocols and national clinical practice guidelines [3] - Comprehensive evaluations and assessments are conducted at every stage of treatment to ensure safety and quality in proton therapy applications [3] Group 5: Patient Experience - The hospital emphasizes a patient-centered service model, featuring case managers who provide detailed explanations of treatment processes and ongoing support throughout the treatment journey [4] - Post-treatment, case managers develop rehabilitation plans and conduct long-term follow-ups to ensure continuous health support for patients [4] Group 6: Future Outlook - The recognition of Guangzhou Taihe Tumor Hospital marks a significant milestone in its development and underscores Meizhong Jiahe's strong capabilities and strategic positioning in the oncology healthcare market [4] - The combination of advanced technology, expert teams, and growing market demand for high-end cancer treatment services positions Meizhong Jiahe for continued competitive advantage and growth opportunities [4]

Core Insights - The article highlights the changes in the Hong Kong Stock Connect holdings, indicating significant increases and decreases in ownership percentages for various companies [1][2][3][4][5] Group 1: Increased Holdings - Delin Holdings (01709) saw the largest increase in ownership percentage, rising by 4.54% to a total holding of 23.11% [1] - Nanjing Panda Electronics (00553) and Lens Technology (06613) also experienced notable increases of 2.35% and 1.73%, bringing their holdings to 45.08% and 3.86% respectively [1] - Over the last five trading days, Changfei Optical Fiber Cable (06869) had the highest increase at 5.47%, with a total holding of 51.43% [3] Group 2: Decreased Holdings - Heng Seng China Enterprises (02828) experienced the largest decrease in ownership, dropping by 4.99% to a holding of 0.51% [2] - Other companies with significant decreases include the Yingfu Fund (02800) and Morning Paper (01812), which saw reductions of 3.03% and 1.11%, resulting in holdings of 1.59% and 42.61% respectively [2] - In the last five trading days, Heng Seng China Enterprises (02828) had a drastic decrease of 14.22%, with a current holding of 0.51% [4] Group 3: Long-term Trends - Over the past 20 days, Changfei Optical Fiber Cable (06869) had the most substantial increase in ownership, up by 23.02% to 51.43% [4] - Other notable increases include Haotian International Investment (01341) and Dongfang Electric (01072), with increases of 18.55% and 12.56% respectively [4] - Conversely, Marco Digital Technology (01942) saw the largest decrease over 20 days, down by 9.44% to a holding of 43.01% [5]

Core Insights - The report highlights significant changes in the shareholding ratios of various companies under the Hong Kong Stock Connect program, indicating shifts in investor sentiment and potential investment opportunities. Group 1: Increased Shareholding Ratios - The companies with the largest increases in shareholding ratios include: - Hang Seng China Enterprises (02828) with an increase of 4.29%, reaching a holding ratio of 19.02% [1][2] - Dongjiang Environmental (00895) with an increase of 2.08%, reaching a holding ratio of 42.98% [1][2] - Meizhong Jiahe (02453) with an increase of 2.02%, reaching a holding ratio of 32.46% [1][2] - Over the last five trading days, the top gainers in shareholding ratios were: - Hang Seng China Enterprises (02828) with an increase of 11.75% [5] - Changfei Optical Fiber (06869) with an increase of 7.15%, reaching a holding ratio of 45.78% [5] - Zhengzhou Bank (06196) with an increase of 3.95%, reaching a holding ratio of 51.58% [5] Group 2: Decreased Shareholding Ratios - The companies with the largest decreases in shareholding ratios include: - Shandong Molong (00568) with a decrease of 3.32%, holding 58.15% [3][4] - Kanglong Chemical (03759) with a decrease of 1.21%, holding 54.05% [3][4] - Green Leaf Pharmaceutical (02186) with a decrease of 1.09%, holding 39.33% [3][4] - Over the last five trading days, the top decliners in shareholding ratios were: - Shandong Xinhua Pharmaceutical (00719) with a decrease of 5.14%, holding 42.62% [6] - Guolian Minsheng (01456) with a decrease of 2.30%, holding 52.59% [6] - Dongfang Electric (01072) with a decrease of 2.06%, holding 40.71% [6] Group 3: Long-term Trends - Over the last 20 trading days, the companies with the largest increases in shareholding ratios included: - Hang Seng China Enterprises (02828) with an increase of 18.02%, holding 19.02% [8] - Changfei Optical Fiber (06869) with an increase of 17.40%, holding 45.78% [8] - Junda Co., Ltd. (02865) with an increase of 14.19%, holding 27.55% [8] - The companies with the largest decreases in shareholding ratios over the last 20 trading days included: - Shijiazhuang Octagon (09676) with a decrease of 13.12%, holding 9.51% [9] - Marco Digital Technology (01942) with a decrease of 9.35%, holding 43.30% [9] - Tigermed (03347) with a decrease of 8.65%, holding 58.37% [9]

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年7月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 美中嘉和醫學技術發展集團股份有限公司 呈交日期: 2025年8月5日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | H | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 02453 | 說明 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 265,151,024 | RMB | | 1 RMB | | 265,151,024 | | 增加 / 減少 (-) | | | 48,723,600 | | | RMB | | 48,723,600 | | 本月底結存 | | | 313,874,624 | RMB | | 1 RMB | | 313,874,624 | | 2. 股份分 ...